Web Stats Provided By Google Analytics

Tuesday, June 6, 2017

Acorda Release: CVT-301 Phase III Data Showed Significantly Improved...

Acorda Release: CVT-301 Phase III Data Showed Significantly Improved Motor Function During OFF Periods In Parkinson's Disease CVT-301 Phase 3 SPAN-PD study met primary endpoint of improvement in UPDRS III, in data presented at 2017 International Congress of Parkinson's Disease and Movement Disorders Company to host investor webcast to review data from CVT-301 clinical program on Monday, June 5 at 4:30 pm Eastern / 1:30 pm Pacific ARDSLEY, N.Y.-- --Acorda Therapeutics, Inc. presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson's Disease Rating Scale - Part III in people with Parkinson's experiencing OFF periods.
http://ift.tt/2sOuJ5Q

No comments:

Post a Comment

Popular Ardsley Roundup Posts